Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 4/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177354 | 0.89 | FYN (0.36) | KDM1AAKT1MAP4K4EP300ROCK1 | |
| SCHEMBL18306341 | 0.86 | ADORA1 (0.42) | KDM1AADORA1MAP4K4ROCK1 | |
| SCHEMBL24716156 | 0.85 | ADORA1 (0.41) | KDM1AADORA1MAP4K4ROCK1 | |
| SCHEMBL24715961 | 0.84 | KDM1A (0.36) | KDM1AAKT1MAP4K4EP300MAOB | |
| SCHEMBL18306449 | 0.84 | KDM1A (0.43) | KDM1AAKT1 | |
| SCHEMBL18306447 | 0.81 | KDM4E (0.40) | KDM1AAKT1MAP4K4DHODHROCK1 | |
| SCHEMBL17177311 | 0.77 | BTK (0.41) | ADORA1 | |
| SCHEMBL18306366 | 0.76 | FYN (0.36) | ADORA1MAP4K4 | |
| SCHEMBL19661452 | 0.75 | KDM1A (0.35) | KDM1AAKT1ROCK1 | |
| SCHEMBL17177310 | 0.74 | ADORA1 (0.42) | ADORA1MAP4K4ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-9518040-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | KDM1A 1981/4885ADORA1 1995/4885AKT1 576/4885 |
| US-20170342048-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | KDM1A 3237/4885ADORA1 1930/4885AKT1 1115/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | KDM1A 1681/4885ADORA1 2057/4885AKT1 472/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | KDM1A 2121/4885ADORA1 2077/4885AKT1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.